Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2012, Article ID 382719, 7 pages
http://dx.doi.org/10.1155/2012/382719
Clinical Study

Diamel Therapy in Polycystic Ovary Syndrome Reduces Hyperinsulinaemia, Insulin Resistance, and Hyperandrogenaemia

Department of Methodology of the Investigation, National Institute of Endocrinology, Havana, MD. Apdo.6275, Habana 6, Cuba

Received 26 August 2011; Revised 18 December 2011; Accepted 8 April 2012

Academic Editor: Ajai Kumar Srivastav

Copyright © 2012 Arturo Hernández-Yero et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Carvajal, C. Herrera, and A. Porcile, “Espectro fenotípico del síndrome de ovarios poliquísticos,” Revista Chilena de Obstetricia y Ginecología, vol. 75, no. 2, pp. 124–132, 2010. View at Google Scholar
  2. P. J. Marsden, A. P. Murdoch, and R. Taylor, “Tissue insulin sensitivity and body weight in polycystic ovary syndrome,” Clinical Endocrinology, vol. 55, no. 2, pp. 191–199, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. R. N. Clayton, V. Ogden, J. Hodgkinson et al., “How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?” Clinical Endocrinology, vol. 37, no. 2, pp. 127–134, 1992. View at Google Scholar · View at Scopus
  4. T. Tsilchorozidou, C. Overton, and G. S. Conway, “The pathophysiology of polycystic ovary syndrome,” Clinical Endocrinology, vol. 60, no. 1, pp. 1–17, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. E. Nestler, “Insulin and ovarian androgen excess,” in Androgen Excess Disorders in Women, R. Azziz, J. E. Nestler, and D. Denally, Eds., pp. 473–483, Lippencott-Raven, Philadelphia, Pa, USA, 1997. View at Google Scholar
  6. J. J. Conn, H. S. Jacobs, and G. S. Conway, “The prevalence of polycystic ovaries in women with type 2 diabetes mellitus,” Clinical Endocrinology, vol. 52, no. 1, pp. 81–86, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. G. M. Prelevic, “Insulin resistance in polycystic ovary syndrome,” Current Opinion in Obstetrics and Gynecology, vol. 9, no. 3, pp. 193–201, 1997. View at Google Scholar · View at Scopus
  8. A. Dunaif and X. Wu, “Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS),” American Journal of Physiology, vol. 281, no. 2, pp. E392–E399, 2001. View at Google Scholar · View at Scopus
  9. L. Ibáñez, C. Valls, N. Potau, M. V. Marcos, and F. De Zegher, “Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect,” Clinical Endocrinology, vol. 55, no. 5, pp. 667–672, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. D. A. Rodin, G. Bano, J. M. Bland, K. Taylor, and S. S. Nussey, “Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women,” Clinical Endocrinology, vol. 49, no. 1, pp. 91–99, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. J. E. Nestler and D. Stovall, “Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 77, no. 2, pp. 209–215, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. E. M. Velazquez, S. Mendoza, T. Hamer, F. Sosa, and C. J. Glueck, “Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy,” Metabolism, vol. 43, no. 5, pp. 647–654, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Vrbíková, M. Hill, L. Stárka et al., “The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome,” European Journal of Endocrinology, vol. 144, no. 6, pp. 619–628, 2001. View at Google Scholar · View at Scopus
  14. S. Palomba, A. Falbo, F. Zullo, and F. Orio, “Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review,” Endocrine Reviews, vol. 30, no. 1, pp. 1–50, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Ünlühizarci, F. Keleştimur, F. Bayram, Y. Şahin, and A. Tutuş, “The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome,” Clinical Endocrinology, vol. 51, no. 2, pp. 231–236, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. T. M. Barber, J. A. H. Wass, M. I. McCarthy, and S. Franks, “Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome,” Clinical Endocrinology, vol. 66, no. 4, pp. 513–517, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Hernández Yero and D. Vargas González, “Evaluación de pacientes con diabetes mellitus tipo 2 en tratamiento con diamel más glibenclamida,” Avances en Diabetología, vol. 23, no. 1, pp. 284–290, 2007. View at Google Scholar
  18. A. Hernández Yero and D. Vargas González, “Beneficial effect of diamel on metabolic control in type 2 diabetic subjects in combined treatment with glibenclamide,” Diabetes and Vascular Disease Research, vol. 4, supplement 1, p. S150, 2007. View at Google Scholar
  19. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome,” Fertility and Sterility, vol. 81, no. 1, pp. 19–25, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. T. M. Wallace, J. C. Levy, and D. R. Matthews, “Use and abuse of HOMA modeling,” Diabetes Care, vol. 27, no. 6, pp. 1487–1495, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. G. S. Buccini and D. L. Wolfthal, “Valores de corte para índices de insulinorresistencia, insulinosensibilidad e insulinosecreción derivados de la fórmula HOMA y del programa HOMA-2,” Revista Argentina de Endocrinologia y Metabolismo, vol. 45, no. 1, pp. 3–21, 2008. View at Google Scholar
  22. E. Raynaud, A. Perez-Martin, J. F. Brun, A. A. Benhaddad, and J. Mercier, “Revised concept for the estimation of insulun sensitivity from a single sample,” Diabetes Care, vol. 22, no. 6, pp. 1003–1004, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Albareda, J. Rodríguez-Espinosa, M. Murugo, A. De Leiva, and R. Corcoy, “Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test,” Diabetologia, vol. 43, no. 12, pp. 1507–1511, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Shroff, C. H. Syrop, W. Davis, B. J. Van Voorhis, and A. Dokras, “Risk of metabolic complications in the new PCOS phenotypes based on the rotterdam criteria,” Fertility and Sterility, vol. 88, no. 5, pp. 1389–1395, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Khattab, I. A. Mohsen, I. A. Foutouh, A. Ramadan, M. Moaz, and H. Al-Inany, “Metformin reduces abortion in pregnant women with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 22, no. 12, pp. 680–684, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. A. J. Stull, K. C. Cash, W. D. Johnson, C. M. Champagne, and W. T. Cefalu, “Bioactives in blueberries improve insulin sensitivity in obese, insulin-resistant men and women,” Journal of Nutrition, vol. 140, no. 10, pp. 1764–1768, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. G. A. Villarreal-Tordecilla, “Estados hiperandrogénicos: revisión de la literatura,” Revista Colombiana de Obstetricia y Ginecología, vol. 60, no. 4, pp. 357–364, 2009. View at Google Scholar